Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

de Almeida Baptista, Marcella Vassão; da Silva, Laís Teodoro; Samer, Sadia; Oshiro, Telma Miyuki; Shytaj, Iart Luca; Giron, Leila B.; Pena, Nathalia Mantovani; Cruz, Nicolly; Gosuen, Gisele Cristina; Ferreira, Paulo Roberto Abrão; Cunha-Neto, Edécio; Galinskas, Juliana; Dias, Danilo; Sucupira, Maria Cecilia Araripe; de Almeida-Neto, Cesar; Salomão, Reinaldo; da Silva Duarte, Alberto José; Janini, Luís Mário; Hunter, James R.; Savarino, Andrea; Juliano, Maria Aparecida; Diaz, Ricardo Sobhie

doi:10.1186/s12981-021-00426-z

Table 1 Demographic characteristics of MDDCT recipients

From: Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

Patient ID	Age (years)	Time since diagnosis (years)	Nadir CD4⁺ T-cell count (cells/mm³)	Screening CD4⁺ T-cell count (cells/mm³)	Pre-ART viral load (copies/mL)	ART regimen		Locus A		Locus B		Locus C		Locus DRB1
Patient ID	Age (years)	Time since diagnosis (years)	Nadir CD4⁺ T-cell count (cells/mm³)	Screening CD4⁺ T-cell count (cells/mm³)	Pre-ART viral load (copies/mL)	Current	Intervention	MHC Class I						MHC Class II
P21	31	10	749	–	98000	TDF + 3TC + FPV + RTV	Dolutegravir + DC	02:AJEBB	03:AJEYV	18:AEDBZ	40:AEDCG	03:AJFXY	03:AJFZD	07:ANCXR	13:AKKUB
P22	54	7	552	1404	364000	AZT + 3TC + EFV	Dolutegravir + DC	01: AJEVP	03:AJEZG	35:AGNUR	44:AGKXV	04:AJTUU	16:AJSFG	04:VVSK	08:AKKFM
P23	26	5	490	693	527795	TDF + 3TC + ATV + RTV	Dolutegravir + DC	01: AJHDX	33:AJHPP	37:AGKTW	58:AGMCF	03:AJSBD	06:AJWYX	04:AEEWN	07:ANBTH
P24	55	22	161	874	480000	TDF + 3TC + EFV	Dolutegravir + DC	01: AJEVS	24:AJFBS	40:AGHBM	51:AGHCW	02:AJRUK	15:AJRUU	04:VVSK	13:AGKBM
P25	43	21	400	1591	102000	TDF + 3TC + LPV + RTV	Dolutegravir + DC	02:AJEXK	24:AJFBM	14:AGRAG	51:ZUDX	02:AJRUK	15:AJRUU	01:ADXMM	08:AGFNT
P26	38	6	530	770	12859	AZT + 3TC + EFV	Dolutegravir + Auranofin + Nicotinamide + DC	24:AJSFV	02:AEDPZ	15:AGRAS	57:BNK	02:AJGWH	03:AJGWT	04:ANEGN	16:ANBUK
P27	24	3	766	839	172029	TDF + 3TC + EFV	Dolutegravir + Auranofin + Nicotinamide + DC	02:AJEAZ	02:AJEAZ	15:AGKPJ	51:AGKZJ	04:AJFYM	14:AGTAE	11:ANTEX	11:AGMJS
P28	44	6	685	1265	57800	TDF + 3TC + EFV	Dolutegravir + Auranofin + Nicotinamide + DC	23:AHPYX	26:AJFCW	14:ADJFT	44:AGRGS	04:AJKCT	08:AJKEG	07:ANCXN	07:ANCXN
P29	49	8	505	677	3300	TDF + 3TC + EFV	Dolutegravir + Auranofin + Nicotinamide + DC	02:AJEBB	03:AJEYV	07:AGKMM	13:AGKNX	06:AJKDJ	07:AJKEA	03:ANCWU	10:VDG
P30	60	13	460	1001	278000	TDF + 3TC + EFV	Dolutegravir + Auranofin + Nicotinamide + DC	02:AJEAZ	02:AJEAZ	07:AGKMF	51:AGMAB	07:AJHZC	16:AJJAB	15:ANBUC	16:ANBUG

HLA genotypes are shown in bold, followed by the National Marrow Donor Program allele codes

Back to article page

ISSN: 1742-6405

Contact us

Submission enquiries: journalsubmissions@springernature.com

AIDS Research and Therapy

Contact us